Highlights of FDA Activities – 9/1/2016 – 9/30/2016

FDA Drug Safety Communications & Drug Information Updates:

Drug Information Update: Drug Safety Labeling Changes 9/1/16
The U.S. Food and Drug Administration has moved the Drug Safety Labeling Changes Program from MedWatch to the CDER Office of Communications, resulting in quicker access to safety-related labeling change information. Labeling changes can now be found in the Drug Safety Labeling Changes (SLC) database which is searchable by drug name or date range.

Drug Information Update: FDA issues final rule on safety and effectiveness of antibacterial soaps 9/2/16
The FDA issued a final rule establishing that over-the-counter consumer antiseptic wash products containing certain active ingredients can no longer be marketed because manufacturers did not demonstrate that the ingredients are both safe for long-term daily use and more effective than plain soap and water in preventing illness and the spread of certain infections. Some manufacturers have already started removing these ingredients from their products. This final rule applies to consumer antiseptic wash products containing one or more of 19 specific active ingredients, including the most commonly used ingredients – triclosan and triclocarban. These products are intended for use with water, and are rinsed off after use. This rule does not affect consumer hand "sanitizers" or wipes, or antibacterial products used in health care settings.

Safety Communication: Ovarian Cancer Screening Tests - FDA Recommends Against Use 9/7/16
The FDA alerted women and their physicians about the risks associated with the use of tests being marketed as ovarian cancer screening tests. The Agency is especially concerned about delaying effective preventive treatments for women who show no symptoms, but who are still at increased risk for developing ovarian cancer. There are currently no screening tests for ovarian cancer that are sensitive enough to reliably screen for ovarian cancer without a high number of inaccurate results. Using unproven ovarian cancer screening tests also may be harmful for women with increased risk for developing ovarian cancer. For instance, these women and their doctors may not take appropriate actions to reduce their future risk if they rely on a result that shows no cancer currently present. Yet, this group of women is still at high risk of developing ovarian cancer later based on their gene mutation and/or family history. The FDA believes that women at high risk for developing ovarian cancer should not use any current screening test for ovarian cancer.

Drug Information Update: 2016 Naloxone App Competition 9/19/16
The FDA announced a public contest to develop a mobile phone application that can connect opioid users and locations with naloxone. Teams and individuals may register until October 7, participate in a two-day code-a-thon at the FDA or virtually on October 19-20, and then submit a video of their functional prototype by November 7, 2016. The winning entrant will receive an award of $40,000. Eligible entrants may also apply for grants to further develop their concepts.

Warning: Homeopathic Teething Tablets & Gels 9/30/16
The FDA warned consumers that homeopathic teething tablets and gels may pose a risk to infants and children. The FDA recommends that consumers discontinue use of these products and dispose of any in their possession. These products have not been evaluated or approved by the FDA. The FDA is currently analyzing reports of adverse events associated with the use of these products, including seizures, and testing product samples.

Major Product Recalls Announced Through MedWatch:

Eye Wash/Eye Irrigating Solutions Distributed by Major Pharmaceuticals and Rugby Laboratories: Recall - Microbial Contamination 9/7/16

United Exchange Corp. of Cerritos, CA, a primary source vendor of the Rugby®-branded Eye Irrigating Solution and Major®-branded Eye Wash, recalled multiple lots of Rugby Eye Irrigating Solution NDC 0536-1083-97 or Major Eye Wash NDC 0904-6491-20 packaged in 4 oz bottles. Affected lot numbers can be found at http://www.fda.gov/Safety/Recalls/ucm519517.htm.

Family Care Eye Wash from United Exchange Corp: Recall - Microbial Contamination 9/8/16

United Exchange Corp. recalled 5 lots of Family Care Eye Wash 4 oz (UPC 780707005828) due to microbial contamination. The affected lot numbers (G15901, G15902, G15903, G15904, and G16909) were distributed nationwide to wholesale and retail facilities.

GlucaGen® HypoKit® (glucagon [rDNA origin] for injection) from Novo Nordisk Inc.: Recall - Detached Needles on the Syringe in the Kit 9/8/16

Novo Nordisk Inc. recalled six batches of the GlucaGen® HypoKit® in the U.S. due to two customer complaints from the UK and Portugal involving detached needles on the syringe with Sterile Water for Injection (SWFI). Affected batches: FS6X270, FS6X296, FS6X538, FS6X597, FS6X797, FS6X875; all with the expiry of 9/30/2017.

Hyoscyamine sulfate from Virtus Pharmaceuticals: Recall - Superpotent and Subpotent Test Results 9/15/16

Virtus Pharmaceuticals Opco II, LLC (Virtus) recalled seven batches of hyoscyamine sulfate 0.125 mg, to the consumer level including the tablet, sublingual, and orally disintegrating tablet forms following detection of both superpotent and subpotent product upon testing. All of these batches were manufactured by Pharmatech LLC for distribution by Virtus throughout the United States and Puerto Rico. Affected NDCs (Batch #'s): NDC 76439-0309-10 (30051601, 30051602, 30051603, 30051604), 76439-0307-10 (30011601), 76439-0308-10 (30031601, 30031602).

Sterile Products from Wells Pharmacy Network: Recall - Uncertainty of Sterility 9/27/16

Sterile human and veterinary products prepared February 22-September 14, 2016 by Wells Pharmacy Network were recalled by the company due to FDA concern that the products do not meet sterility assurance standards.

Dietary Supplement Recalls & Public Notifications

In September, the FDA issued notifications to the public regarding undeclared active ingredients in the following products. Patients are advised not to purchase or use these products.

Product	*Promoted Use*	*Hidden/Undeclared Drug Ingredient(s)*
Stiff Bull Herbal Coffee	Improving energy	Desmethyl carbodenafil[1]

[1] Related to sildenafil: may interact with nitrates to lower blood pressure to dangerous levels

New Product Shortages Reported by the FDA:	*Date Initially Posted*
Scopolamine Transdermal System Patch (Transderm Scop, Sandoz)	9/15/16
Transderm Scop 1.5 mg patches (NDCs: 10019-553-01, 10019-553-02, 0067-4345-04)	
Water-Miscible Vitamin A Palmitate (Aquasol A Parenteral, Hospira)	9/16/16
50,000 USP Units/mL (15 mg retinol/mL); 100,000 Units/2 mL (30 mg retinol/2 mL) Single Dose Glass Fliptop Vial (NDC 61703-418-18).	
Etoposide Phosphate Injection (Etopophos, Bristol Myers Squibb)	9/16/16
Etopophos Injection 100 mg (1VL) 10.6 mL US (NDC 0015-3404-20).	
Ketoprofen Capsules (Mylan)	9/19/16
200 mg extended-release capsules, 100 count bottle (NDC 0378-8200-01).	
Procainamide HCl injection, USP (Hospira)	9/27/16
100 mg/ml; 1,000 mg/10 ml multiple dose glass fliptop vial (NDC 0409-1902-01)	
500 mg/ml; 1,000 mg/2 ml multiple dose glass fliptop vial (NDC 0409-1903-01)	

Product Discontinuations/Withdrawals	***Date Posted***
Oxazepam Capsules 10 mg, 15 mg, 30 mg, Sandoz (NDC 0781-28-0901, 0781-28-1001, 0781-28-1101) Generic equivalents available.	9/2/16
Technetium Tc99M Succimer Injection (DMSA Kit, GE Healthcare) (NDC 17156-525-01)	9/30/16
Telbivudine (Tyzeka, Novartis) 600 mg tablets (NDC 0078-0538-15) No generic equivalent available; an alternative antiviral for chronic hepatitis B should be selected.	9/30/16

New Drug Approvals:	***Description***	***Date Approved***
Eteplirsen / Exondys 51 / Sarepta	See attached drug summary	9/19/16
Adalimumab-atto / Amjevita / Amgen	Amjevita is approved as a biosimilar to Humira (adalimumab) for most of the same indications (rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, adult Crohn's disease, and ulcerative colitis). Warnings and cautions are identical. Dosing is identical for the shared indications, although the biosimilar is available only as a 40 mg single-use autoinjector, and 40 mg/0.8 mL and 20 mg/0.4 mL prefilled syringes.	9/23/16

New Indications:	***Description***	***Date Approved***
Ustekinumab / Stelara / Janssen	Indication expanded to include Crohn's disease in patients who have failed or were intolerant to immunomodulators or corticosteroids or one or more TNF blockers. Initial dose is weight based, with patients less than 55 kg receiving 260 mg, patients between 55 and 85 receiving 360 mg, and patients over 85 kg receiving 520 mg, all as IV infusions over at least 1 hour. Subsequent infusions are 90 mg IV every 8 weeks.	9/23/16
Canakinumab / Ilaris / Novartis	Indication expanded to include the treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), and Familial Mediterranean Fever (FMF).	9/23/16
Lumacaftor & ivacaftor / Orkambi / Vertex Pharmaceuticals	Indication expanded to include use in children 6 to 11 years with cystic fibrosis and two copies of the F508del mutation in the CF transmembrane conductance regulator gene.	9/29/16

New Dosage Forms or Formulation:	***Description***	***Date Approved***
Aspirin & omeprazole delayed-release tablets / Yosprala / Aralez Pharmaceuticals	Combination tablets containing 81 mg delayed-release aspirin & 40 mg immediate-release omeprazole or 325 mg delayed-release aspirin & 40 mg immediate-release omeprazole. Administered once daily at least 60 minutes before a meal for patients requiring aspirin for secondary prevention for cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers.	9/14/16
Levonorgestrel IUD / Kyleena / Bayer	Progestin-releasing intrauterine system indicated for prevention of pregnancy for up to 5 years	9/16/16
Enalapril maleate oral solution / Epaned / Silvergate Pharmaceuticals	Ready to use oral solution containing 1 mg/ml enalapril maleate.	9/20/16
Canagliflozin & metformin / Invokamet XR / Janssen Pharmaceuticals	Each tablet contains 50 mg canagliflozin and 500 mg metformin in a once a day formulation.	9/20/16

Compiled by:

Terri Levien, Pharm.D.
Zaynah Ali, Pharm.D., PGY1 Drug Information Resident
David Platt, Pharm.D. Candidate 2017
Christopher Robinett, Pharm.D. Candidate 2017
James Robeson, Pharm.D. Candidate 2017
Alice Knotts, Pharm.D. Candidate 2018
Uzoma Mbogu, Pharm.D. Candidate 2018

Drug Information Center
College of Pharmacy
Washington State University
PO Box 1495
Spokane, WA 99210-1495
(509) 358-7662
Pharmacy.druginfo@wsu.edu

Eteplirsen / Exondys 51 / Sarepta Therapeutics	
Generic Name / Brand Name / Company	Eteplirsen/ Exondys 51/ Sarepta Therapeutics
Date of approval	September 19, 2016
Drug Class (Mechanism of Action if novel agent)	Eteplirsen is designed to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing.
Indication	Treatment of Duchenne muscular dystrophy (DMD) in patients with confirmed mutation of the MDM gene that is amenable to exon 51 skipping.
Comparative agent – Therapeutic interchange?	None
Dosage forms/strengths. Common Dose/sig	Injection: 100 mg/2 mL (50 mg/mL) solution in a single-dose vial Injection: 500 mg/10 mL (50 mg/mL) solution in a single-dose vial Dose: 30 mg/kg of body weight as an intravenous infusion once weekly
DEA Schedule	Not scheduled
Date of market availability	9/19/2016
Similar Medications (Look-Alike Sound-Alike)	Etanercept, etodolac
Clinical Use Evaluation	
Common Adverse Effects	Balance disorder and vomiting
Severe Adverse Effects	None known
Severe Drug-Drug Interactions	Based on *in vitro* data on plasma protein binding, CYP or drug transporter interactions, and microsomal metabolism, eteplirsen is expected to have a low potential for drug-drug interactions in humans
Severe Drug-Food Interactions	None known
Important Labs Values to assess prior to order entry or at point of clinical follow up. (Need Pop Up?)	DMD genotype
Used in Pediatric Areas	Safety and effectiveness has been established in pediatric patients
Renal or Hepatic Dosing	Eteplirsen has not been studied in patients with renal or hepatic impairment
Critical Issues (i.e., contraindications, warnings, etc) that should be emphasized	None listed in prescribing information
Special administration technique or considerations	• May apply topical anesthetic cream to infusion site prior to administration. • Administer as an intravenous infusion over 35 to 60 minutes • Dilution in 0.9% Sodium Chloride Injection, USP, required prior to administration • Flush the line with 0.9% Sodium Chloride Injection, USP, before and after infusion
Prepared by	Uzoma Mbogu, Pharm.D. Candidate 2018
Source	Exondys 51 [package insert]. Cambridge, MA: Sarepta Therapeutics, Inc.; September 2016.